Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ 9-tetrahydrocannabinol) discrimination for rats

Behavioural Pharmacology

Volumn 22, Issue 5-6, 2011, Pages 498-507

  Järbe, Torbjörn U C ^a,b   Deng, Hongfen ^b   Vadivel, Subramanian K ^b   Makriyannis, Alexandros ^b  

^a TEMPLE UNIVERSITY   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

AM2233; AM5983; AM678= JWH018; cannabinergic aminoalkylindoles; drug discrimination; rat; rimonabant; tetrahydrocannabinol; WIN55212 2

Indexed keywords

(2 IODOPHENYL)[1 [(1 METHYLPIPERIDIN 2 YL)METHYL] 1H INDOL 3 YL]METHANONE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (1 NAPHTHOYL) 1 PENTYLINDOLE; [1 [(1 METHYLPIPERIDIN 2 YL)METHYL] 1H INDOL 3 YL](NAPHTHALEN 1 YL)METHANONE; AM 2233; AM 5983; AM 678; AMINE; CANNABINOID DERIVATIVE; DRONABINOL; INDOLE DERIVATIVE; NAPHTHALEN 1 YL (1 PENTYL 1H INDOL 3 YL)METHANONE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; MALE; NONHUMAN; RAT;

ANIMALS; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; INJECTIONS, INTRAPERITONEAL; LIGANDS; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 80051920710     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e328349fbd5     Document Type: Article

References (42)

1. Atwood BK, Huffman J, Straiker A, Mackie K (2010). JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 160:585-593.
2. Atwood BK, Lee D, Straiker A, Widlanski TS, Mackie K (2011). CP47,497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol 659:139-145.
3. Aung MM, Griffin G, Huffman JW, Wu M, Keel C, Yang B, et al. (2000). Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend 60:133-140. (Pubitemid 30625016)
4. Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (2000). Agonist efficacy, drug dependence, and medications development: pre-clinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands. Psychopharmacology (Berl) 153:67-84.
5. Bosier B, Muccioli GG, Hermans E, Lambert DM (2010). Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 80:1-12.
6. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR (1992). Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta-9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126. (Pubitemid 23157189)
7. De Vry J, Jentzsch KR (2002). Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist. Eur J Pharmacol 457:147-152. (Pubitemid 35447656)
8. De Vry J, Jentzsch KR (2004). Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat. Eur J Pharmacol 505:127-133. (Pubitemid 39535684)
9. Deng H, Gifford AN, Cui G, Li X, Fan P, Deschamps JR, et al. (2005). Potent cannabinergic indole analogs as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. J Med Chem 48:6386-6392. (Pubitemid 41428990)
10. Devane WA, Breuer A, Sheskin T, Järbe TUC, Eisen MS, Mechoulam R (1992). A novel probe for the cannabinoid receptor. J Med Chem 35:2065-2069.
11. Dhawan J, Deng H, Gatley SJ, Makriyannis A, Akinfeleye T, Bruneus M, et al. (2006). Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Synapse 60:93-101. (Pubitemid 43878117)
12. Extance K, Goudie AJ (1981). Inter-animal olfactory cues in operant drug discrimination procedures in rats. Psychopharmacology (Berl) 73:363-371. (Pubitemid 11114123)
13. Hodge CW, Grant KA, Becker HC, Besheer J, Crissman AM, Platt DM, et al. (2006). Understanding how the brain perceives alcohol: neurobiological basis of ethanol discrimination. Alcohol Clin Exp Res 30:203-213. (Pubitemid 43341370)
14. Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, Wood DM (2010). Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in 'herbal high' products. J Anal Toxicol 34:252-260.
15. Huffman JW, Padgett LW (2005). Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr Med Chem 12:1395-1411. (Pubitemid 40872583)
16. Huffman JW, Dai D, Martin BR, Compton DR (1994). Design, synthesis and pharmacology of cannabimimetic indoles. Bioorg Med Chem Lett 4: 563-566. (Pubitemid 24131892)
17. Järbe TUC (1989). Discrimination learning with drug stimuli: methods and applications. In: Boulten AA, Baker GB, Greenshaw AJ, editors. Neuro-methods: Psychopharmacology. Vol. 13: Clifton, NJ: Humana Press. . pp. 513-563.
18. Järbe TUC (2011). Perceptual drug discriminative aspects of the endocannabi-noid signaling system in animals and man. In: Glennon RA, Young R, editors. Drug discrimination: applications to medicinal chemistry and drug studies. Hoboken, NJ: Wiley Publ. Co., in press
19. Järbe TUC, Swedberg MD, Mechoulam R (1981). A repeated test procedure to assess onset and duration of the cue properties of (-) D9-THC, (-) D8-THC-DMH and (+) D8-THC. Psychopharmacology (Berl) 75:152-157. (Pubitemid 12228822)
20. Järbe TUC, Hiltunen AJ, Lander N, Mechoulam R (1986). Cannabimimetic activity (delta-1-THC cue) of cannabidiol monomethyl ether and two stereoisomeric hexahydrocannabinols in rats and pigeons. Pharmacol Biochem Behav 25:393-399. (Pubitemid 16045863)
21. Järbe TUC, Hiltunen AJ, Mechoulam R (1989). Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-D8-tetrahydrocannabinol in rats and pigeons. J Pharmacol Exp Ther 250:1000-1005. (Pubitemid 19246712)
22. Järbe TUC, Lamb RJ, Lin S, Makriyannis A (2001). (R)-methanandamide and D9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) 156:369-380. (Pubitemid 32695845)
23. Järbe TUC, Li C, Vadivel SK, Makriyannis A (2010). Discriminative stimulus functions of methanandamide and D9-THC in rats: tests with aminoalk-ylindoles (WIN55212-2 and AM678) and ethanol. Psychopharmacology (Berl) 208:87-98.
24. Little PJ, Compton DR, Mechoulam R, Martin BR (1989). Stereochemical effects of 11-OH-delta-8-THC-dimethylheptyl in mice and dogs. Pharmacol Biochem Behav 32:661-666. (Pubitemid 19162385)
25. Manera C, Tuccinardi T, Martinelli A (2008). Indoles and related compounds as cannabinoid ligands. Mini Rev Med Chem 8:370-387. (Pubitemid 351606778)
26. Mauler F, Mittendorf J, Horvath E, De Vry J (2002). Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4, 4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 302: 359-368. (Pubitemid 34680459)
27. McMahon LR (2006a). Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating D9-tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211-1218.
28. McMahon LR (2006b). Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with D9-tetrahydro- cannabinol. Psychopharmacology (Berl) 188:306-314. (Pubitemid 44387458)
29. McMahon LR, Ginsburg BC, Lamb RJ (2008). Cannabinoid agonists differentially substitute for the discriminative stimulus effects of D9-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology (Berl) 198:487-495. (Pubitemid 351754667)
30. Nguyen PT, Selley DE, Sim-Selley LJ (2010). Statistical parametric mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain. Neuroimage 52:1243-1251.
31. Pério A, Rinaldi-Carmona M, Maruani J, Barth F, Le Fur G, Soubrié P (1996). Central mediation of the cannabinoid cue: activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 7:65-71. (Pubitemid 26051785)
32. Pertwee RG (2008). Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 13:147-159. (Pubitemid 351698890)
33. Pertwee RG (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17:1360-1381.
34. Poso A, Huffman JW (2008). Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. Br J Pharmacol 153:335-346.
35. Sidman M (1960). Tactics of Scientific Research-Evaluating Experimental Data in Psychology. New York, NY: Basic Books.
36. Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, et al. (2007). The endogenous cannabinoid anandamide produces delta-9-tetrahydrocan- nabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. J Pharmacol Exp Ther 321:370-380. (Pubitemid 46456957)
37. Stewart JL, McMahon LR (2010). Rimonabant-induced D9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther 334:347-356.
38. Thakur GA, Nikas SP, Li C, Makriyannis A (2005). Structural requirements for cannabinoid receptor probes. Hand Exp Pharm 168:209-246.
39. Uchiyama N, Kikura-Hanajiri R, Matsumoto N, Huang ZL, Goda Y, Urade Y. Effects of synthetic cannabinoids on electroencephalogram power spectra in rats. Forensic Sci Int 2011.
40. Vardakou I, Pistos C, Spiliopoulou C (2010). Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 197:157-162.
41. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR (1995). Discriminative stimulus effects of CP 55 940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 34:669-676.
42. Wiley JL, Compton DR, Dai D, Lainton JA, Phillips M, Huffman JW, Martin BR (1998). Structure-activity relationships of indole-and pyrrole-derived cannabinoids. J Pharmacol Exp Ther 285:995-1004. (Pubitemid 28277896)